Drug Patent Watch
JULY 1, 2021
This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
In line with the political objectives of the EU Green Deal, the program’s main goal is to fight climate change by establishing carbon farming practices at farmers’ level with benefits for the entire agricultural value chain / Program kicks off with over 25 farmers across seven countries in the EU and beyond: France, Spain, Belgium, Denmark, Germany, United Kingdom and Ukraine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 27, 2021
Happy 245th birthday, America! As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. P.S.
Drug Patent Watch
JULY 2, 2021
Annual Drug Patent Expirations for NOXAFIL Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. It is available from three suppliers. There…. The post New patent for Merck Sharp drug NOXAFIL appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JULY 2, 2021
This chart shows the pharmaceutical companies with the most film dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most film dosed drugs…. The post Which pharmaceutical companies have the most film dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 28, 2021
Annual Drug Patent Expirations for BESIVANCE Besivance is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from two suppliers. There are five…. The post New patent expiration for Bausch And drug BESIVANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JULY 2, 2021
Annual Drug Patent Expirations for PERSERIS+KIT Perseris Kit is a drug marketed by Indivior Inc and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Indivior Inc drug PERSERIS KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2021
Annual Drug Patent Expirations for NATROBA Natroba is a drug marketed by Parapro Llc and is included in one NDA. It is available from two suppliers. There are two patents…. The post New patent expiration for Parapro Llc drug NATROBA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JULY 1, 2021
Annual Drug Patent Expirations for LORBRENA Lorbrena is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Pfizer drug LORBRENA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
This chart shows the pharmaceutical companies with the most patents in Australia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Australia? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for LEXETTE Lexette is a drug marketed by Mayne Pharma and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Mayne Pharma drug LEXETTE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for RHOPRESSA Rhopressa is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent for Aerie Pharms drug RHOPRESSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for ROCKLATAN Rocklatan is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are eleven…. The post New patent for Aerie Pharms drug ROCKLATAN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for NURTEC+ODT Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug. NURTEC ODT…. The post New patent for Biohaven Pharm drug NURTEC ODT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
JUNE 30, 2021
Annual Drug Patent Expirations for TRIKAFTA+%28COPACKAGED%29 Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Vertex Pharms drug TRIKAFTA (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 30, 2021
Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Opdivo plus Yervoy is the first dual immunotherapy regimen approved in the European Union for colorectal cancer. Opdivo plus Yervoy- based combinations now indicated in the European Union for five different advanced cancer types: mesothelioma, non-small cell lung cancer, melanoma, renal cell carcinoma and colorectal cancer.
The Pharma Data
JUNE 30, 2021
Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care — — Study Met the Primary and Key Secondary Endpoints of Event-Free Survival and Objective Response Rate, Demonstrating a Highly Statistically and Clinically Significant Improvement Compared to Standard of Care — Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of ZUMA-7, a
The Pharma Data
JUNE 30, 2021
he board of directors of Eli Lilly and Company (NYSE: LLY) (the “Board”) has declared a dividend for the third quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on September 10, 2021 to shareholders of record at the close of business on August 13, 2021. About Eli Lilly and Company?. Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
JUNE 30, 2021
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their outstanding work into feline SARS-CoV-2 infections and feline leukaemia virus, respectively Boehringer Ingelheim has been sponsoring the award since 2008 to help foster talent development in the feline health research community Award represents important collaboration between Boehringer Ingelheim and the Advisory Board on Cat Diseases (ABCD).
The Pharma Data
JUNE 30, 2021
Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitors This analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 2021 1 EMPRISE data complement the landmark EMPA-REG OUTCOME
The Pharma Data
JUNE 29, 2021
If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease. AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the DAPA-CKD Phase III
The Pharma Data
JUNE 29, 2021
AstraZeneca today appointed Dr. Susan Galbraith to lead Oncology Research & Development from initial discovery through late-stage development. Her appointment follows the passing of José Baselga earlier this year. She will join the Company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot. Susan previously led early-stage Oncology R&D, overseeing the successful progression of seven programmes into Phase III trials, with four new medicines now approved in countr
The Pharma Data
JUNE 29, 2021
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. The results, published by the University of Oxford on the pre-print server of The Lancet , demonstrated that antibody levels remain elevated from baseline for at least one year following a single dose.
The Pharma Data
JUNE 29, 2021
New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin. A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin (
The Pharma Data
JUNE 29, 2021
Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021. Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the comp
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK). (“Takeda”) today announced new assignment of Directors. The details are as follows; Directors Who are Not Audit and Supervisory Committee Members. New assignment of Non-Audit and Supervisory Committee Directors effective June 29, 2021; Name Category Expected Role Christophe Weber Internal Existing Representative Director,President & Chief Executive Officer Masato Iwasaki Internal Existing Representative Director, Japan General Affair
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (“Company”) announced today that after the Company withdraws the Shelf Registration Statement regarding the issuance of new shares filed on June 24, 2020, it will file a Shelf Registration Statement in Japan regarding the issuance of new shares. The purpose of the filing is to issue shares of common stock of the Company in a timely and flexible manner in association with the continued implementation of a Long Term Incentive Plan (“LTIP”).
The Pharma Data
JUNE 30, 2021
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: [link].
The Pharma Data
JUNE 30, 2021
– Significantly more upadacitinib-treated (15 mg or 30 mg, once daily) patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to patients on placebo at one-year (week 52) (p<0.001)[1] – All secondary endpoints were met, including the achievement of endoscopic improvement, HEMI and corticosteroid-free clinical remission at one-year (p<0.001)[1] – Safety results were consistent with the previous Phase 3 induction studies and the kno
The Pharma Data
JUNE 29, 2021
Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l’Etoile, Lyon (France). “During the COVID-19 pa
The Pharma Data
JUNE 29, 2021
Latest modelling analysis from Public Health England (PHE) and the University of Cambridge’s MRC Biostatistics Unit suggests that the coronavirus (COVID-19) vaccination programme has so far prevented an estimated 7.2 million infections and 27,000 deaths in England alone. This is the first analysis giving an estimated number of vaccine-prevented infections, providing further evidence of the staggering impact of the vaccination programme so far.
Drug Patent Watch
JUNE 28, 2021
Pharmaceutical drug patents enable branded drug companies to prevent market entry by competitors until the patents expire. The term of drug patents varies. The basic term for a patent is…. The post Future drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 28, 2021
Annual Drug Patent Expirations for EPANED Epaned is a drug marketed by Azurity and Silvergate Pharms and is included in two NDAs. It is available from one supplier. There are…. The post New patent for Azurity drug EPANED appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
84 
Let's personalize your content